| Risk of death among persons with CD4≤200 cells/μL from other causes over 90 days |
0.0353 |
[27] |
| CD4≤200 cells/μL Histoplasma antigen screened |
0.8 |
Assumption |
| Return to clinic for Histoplasma antigen results |
1 |
Assumption |
|
Histoplasma antigen prevalence |
|
|
| Histoplasma negative |
0·908 |
[9, 10] |
| Histoplasma positive |
0·092 |
[11, 28] |
|
Histoplasma antigen positive, symptomatic |
0·88 |
[29, 30] |
| Symptomatic hospitalized |
0·80 |
Assumption |
| Among people screened and positive for Histoplasma antigen, conventional diagnostics performed |
0·05 |
Assumption |
|
Histoplasma antigen positive and conventional diagnostics positive |
0·77 |
[6] |
| Absence of Histoplasma antigen screening, conventional diagnostics performed among symptomatic hospitalized |
0·60 |
Assumption |
| Absence of Histoplasma antigen screening, conventional diagnostics performed among symptomatic non-hospitalized |
0·30 |
Assumption |
| Symptomatic, known Histoplasma antigen positive, receives antifungal treatment |
0·90 |
Assumption |
| Symptomatic, conventional diagnostics positive, receives antifungal treatment |
0·90 |
Assumption |
| Symptomatic, conventional diagnostics negative, receives antifungal treatment |
0·20 |
Assumption |
| Symptomatic, conventional diagnostics not performed, receives antifungal treatment |
0·30 |
Assumption |
| Asymptomatic Histoplasma antigen positive |
0·12 |
[29, 30] |
| Absence of Histoplasma screening, receives antifungal treatment |
0 |
Assumption |
| Presence of Histoplasma screening, receives antifungal treatment |
0.9 |
Assumption |
|
Histoplasmosis-positive outcomes
|
|
|
| Asymptomatic histoplasmosis outcomes |
|
|
| 30-day mortality if treated with antifungals |
0·10 |
Assumption |
| 30-day mortality if not treated with antifungals |
0·10 |
Assumption |
| Symptomatic histoplasmosis outcomes |
|
|
| 30-day mortality if treated with antifungals |
0·13 |
[7, 11, 28] |
| 30-day mortality without antifungal treatment |
0·65 |
[14] |
